Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).
The investigators recorded clinical factors, serum levels of glucose, HbA1c, lipids and LP-PLA2 in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016. The relationship between levels of LP-PLA2 and diabetic complications are analysed.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Lipoprotein-associated Phospholipase A2 | the plasma lipoprotein-associated phospholipase A2 level of patients | Day one |
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c | the glycosylated hemoglobin level of patients | Day one |
| LDL-c | low density lipoprotein cholesterol | Day one |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with type 2 diabetes who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to August 2016 were enrolled in this study.
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30904742 | Derived | Hu Y, Li TT, Zhou W, Lu TT, Li FF, Ding B, Liu BL, Xie XJ, Ma JH. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease. Diabetes Res Clin Pract. 2019 Apr;150:194-201. doi: 10.1016/j.diabres.2019.03.026. Epub 2019 Mar 20. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Patients With T2DM | Patients with type 2 diabetes |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Patients With T2DM | Patients with type 2 diabetes |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Lipoprotein-associated Phospholipase A2 | the plasma lipoprotein-associated phospholipase A2 level of patients | Posted | Mean | Standard Deviation | ng/ml | Day one |
|
|
Not provided
Serious, and Other Adverse Events were not assessed.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Patients With T2DM | Patients with type 2 diabetes |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ma Jianhua | Nanjing First Hospital | 8625-52887092 | majianhua196503@126.com |
Not provided
Not provided
Not provided
Not provided
| Diabetic Complication | the prevalence of atherosclerosis, diabetic Nephropathy, diabetic retinopathy and diabetic neuropathy | Day one |
| C Peptide | fast and 120min postprandial C peptide | Day one |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
|
| Secondary | HbA1c | the glycosylated hemoglobin level of patients | Posted | Mean | Standard Deviation | percentage of glycated hemoglobin | Day one |
|
|
|
| Secondary | LDL-c | low density lipoprotein cholesterol | Posted | Mean | Standard Deviation | mmol/L | Day one |
|
|
|
| Secondary | Diabetic Complication | the prevalence of atherosclerosis, diabetic Nephropathy, diabetic retinopathy and diabetic neuropathy | Not Posted | Day one | Participants |
| Secondary | C Peptide | fast and 120min postprandial C peptide | Not Posted | Day one | Participants |
| 0 |
| 0 |
| 0 |
| 0 |
Not provided
Not provided
Not provided